Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Taylor Swift and Travis Kelce doing Coachella in style! They will be staying at a TOP luxury membersSheffield United face twoAuckland Transport to be stripped of planning powersCleanup of homeless encampment along Santa Ana River hits a snag in Newport BeachBayern Munich kick a ball around a £3,500Jurgen Klopp insists Liverpool's 2ULTIMATE GRAND NATIONAL GUIDE: Mail Sport's expert gives his verdict on all 34 runnersMan United fan Mark Goldbridge's xBayern Munich kick a ball around a £3,500Scary Movie is back! Franchise will be rebooted 11 years after Scary Movie 5 was released
2.742s , 6491.03125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Insight news portal